Coronavirus (COVID-19), première indication de l’efficacité de Gene-Eden-VIR / Novirin dans les infections à SRAS-CoV-2

Gene-Eden-VIR™ and Novirin® are trademarks and registered marks.
*Based on clinical studies published in the medical journals Drug Design, Development and Therapy, Clinical and Translational Medicine, Journal of Evidence-Based Integrative Medicine, and Pharmacology and Pharmacy
†These statements have not been evaluated by the Food and Drug Administration. This product does not guarantee to diagnose, treat, cure or prevent any disease. Results may vary from person to person.